Noseland: The clinical protocol for phase IIc of project NL005 has been basically finalized. There are currently no effective treatment drugs in this field worldwide.

Norseland released an investor relations activity record, NL005 is a type 1 new drug that the company is focusing on developing. It is expected to reduce reperfusion injury caused by myocardial infarction through a mechanism of myocardial protection. There is currently no effective therapeutic drug in this area worldwide, so if successfully developed, the market prospect is promising. However, on the other hand, as an innovative drug with a completely new target, the development of NL005 is facing challenges due to the lack of similar drugs to refer to for research and development experience. Currently, the phase II clinical trial protocol for the NL005 project has been basically determined, and communication and selection of participating research centers are ongoing.